Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez

Company Presents HOPE-B Data At R&D Day

Executive Summary

The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.

You may also be interested in...



Novartis Can Again Pursue Bigger Zolgensma Market After FDA Lifts OAV-101 Hold

Novartis aims to double the addressable market for its spinal muscular atrophy gene therapy – and catch up to competitors – with the intrathecal version known as OAV-101.

Sigilon Hemophilia Cell Therapy On Clinical Hold, But May Not Be Drug-Related

A patient developed Factor VIII inhibitors, but he had also recently received a COVID-19 vaccine and was genetically predisposed.

Again Please: BioMarin Seeks Speedy EU Review For Hemophilia Gene Therapy

BioMarin is planning to resubmit its EU marketing application for Roctavian soon and, as with the previously pulled application, it wants the regulators to fast-track the new filing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel